1/13
05:44 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
1/12
08:04 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.
Low
Report
Neumora Therapeutics (NASDAQ:NMRA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.
1/5
01:08 pm
nmra
Neumora Therapeutics (NASDAQ:NMRA) was given a new $6.00 price target on by analysts at Mizuho.
Low
Report
Neumora Therapeutics (NASDAQ:NMRA) was given a new $6.00 price target on by analysts at Mizuho.
1/5
06:53 am
nmra
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones [Yahoo! Finance]
High
Report
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones [Yahoo! Finance]
1/5
06:35 am
nmra
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation [Yahoo! Finance]
High
Report
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation [Yahoo! Finance]
1/5
06:35 am
nmra
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
High
Report
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
1/5
06:30 am
nmra
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
Medium
Report
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
1/3
06:28 am
nmra
RBC Sees Upside Potential in Neumora Therapeutics (NMRA) [Yahoo! Finance]
Low
Report
RBC Sees Upside Potential in Neumora Therapeutics (NMRA) [Yahoo! Finance]
12/1
07:03 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating.
Neutral
Report
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating.
11/17
09:21 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Stifel Nicolaus from $2.00 to $3.00. They now have a "hold" rating on the stock.
Low
Report
Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Stifel Nicolaus from $2.00 to $3.00. They now have a "hold" rating on the stock.
11/6
08:04 am
nmra
Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02 [Seeking Alpha]
Medium
Report
Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02 [Seeking Alpha]
11/6
07:00 am
nmra
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
11/3
07:00 am
nmra
Neumora Therapeutics to Participate in Upcoming Conferences in November
Low
Report
Neumora Therapeutics to Participate in Upcoming Conferences in November
10/28
08:09 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Needham & Company LLC from $6.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Needham & Company LLC from $6.00 to $8.00. They now have a "buy" rating on the stock.
10/27
08:34 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $14.00 price target on the stock.
Medium
Report
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $14.00 price target on the stock.
10/27
07:00 am
nmra
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Medium
Report
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
10/27
06:30 am
nmra
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Medium
Report
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model